ACAD Stock Soars as US Court Rules in Favor of Key Nuplazid Patent
Acadia stock jumps 27% after winning a key patent case for Nuplazid, which will protect the drug's U.S. sales from generic erosion till 2038.
ACADIA Pharmaceuticals: Advancing On Several Fronts
ACADIA Pharmaceuticals posted better-than-expected Q1 results earlier this month. The company has a rock solid balance sheet and advancing a couple of key drug candidates within its pipeline. An updated analysis around ACADIA Pharmaceuticals follows in the paragraphs below.
Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates (Revised)
Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of $0.10 per share. This compares to earnings of $0.10 per share a year ago.
Acadia Q1 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth
ACAD reports encouraging first-quarter results as earnings and revenues beat estimates, driven by year-over-year growth in Nuplazid and Daybue sales.
ACADIA Pharmaceuticals Inc. (ACAD) Q1 2025 Earnings Conference Call Transcript
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Al Kildani - SVP of IR & Corporate Communications Catherine Owen Adams - CEO Tom Garner - COO Elizabeth Thompson - EVP and Head of R&D Mark Schneyer - EVP and CFO Conference Call Participants Ritu Baral - TD Cowen Tessa Romero - JPMorgan Ash Verma - UBS Elaine Kim - Canter Basma Radwan - Leerink Partners David Huang - Deutsche Bank Tazeen Ahmad - Bank of America Yatin Suneja - Guggenheim Joel Beatty - Baird Sumant Kulkarni - Canaccord Genuity Malcolm Hoffman - BMO Capital Markets Operator Good day, ladies and gentlemen, and welcome to the ACADIA Pharmaceuticals Conference Call. My name is Lauren Cannon, and I'll be your coordinator for today.
Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates
Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of $0.10 per share. This compares to earnings of $0.10 per share a year ago.
5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates
Let us look at some drug/biotech stocks, NVO, PCRX, RARE, ACAD and DNLI, which are poised to beat on first-quarter 2025 earnings.
Earnings Preview: Acadia Pharmaceuticals (ACAD) Q1 Earnings Expected to Decline
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Acadia (ACAD) Stock Jumps 6.1%: Will It Continue to Soar?
Acadia (ACAD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Why Is Acadia (ACAD) Down 11.1% Since Last Earnings Report?
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in the following virtual investor conferences: UBS Virtual CNS Day 2025 Fireside Chat: Monday, March 17, 2025 at 11:00 a.m. Eastern Time Stifel 2025 Virtual CNS Forum Fireside Chat: Wednesday, March 19, 2025 at 12:30 p.m. Eastern Time 24th Annual Needham Virtual Healthcare Conference Fireside Chat: Monday, April 7, 2025 at 10:15 a.m. Eastern Time Live webcasts of each fireside chat wi.
Clinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Med
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the journal Med published results from the open-label study, DAFFODIL™, evaluating the safety, tolerability and exploratory efficacy of DAYBUE® (trofinetide) in girls ages two to four living with Rett syndrome (n = 15). The long-term Phase 2/3 study demonstrated DAYBUE had a similar safety profile in children two to four years of age as that observed in individuals with Rett syndrome five years of age an.
